Navigation Links
Patient Advocate for CancerConnect.com and Acclaimed Writer, Jamie Reno, Delivers Devastating News of Lifesaving Cancer Drug's Discontinuation
Date:8/26/2013

San Diego, CA (PRWEB) August 26, 2013

According to Jamie Reno, an award-winning correspondent for Newsweek, he received a note from GlaxoSmithKline spokesperson, Bernadette King, on August 7th saying that the company would halt the manufacturing and sale of Bexxar on February 14th 2014. Reno immediately then posted the story to his national news blog, The Reno Dispatch. Further citation can also be found at PipelineReview.com in their report published August 6, 2013. The post indicates the many problems with discontinuing the cancer drug and discusses why the drug many have been cancelled in the first place. For Reno, it was a personal blow.

Reno has been in remission for more than thirteen years because of Bexxar, and he has spoken with countless other survivors who wouldn't be here today if it weren't for radio-immunotherapy in the form of Bexxar and its competitor, Zevalin. Although the spokesperson for GSK said they tried to make the drug available to patients through a wide range of options, Reno disputes their claim that their ultimate decision was the correct one. GSK says that they plan to make the cell line that is responsible for the production of Bexxar available for research purposes. Zevalin, which is manufactured by Spectrum Pharmaceuticals, will remain on the market but is also in financial trouble, according to both Reno and Nasdaq.com on August 8, 2013.

Bexxar is a form of radio-immunotherapy that is used to tread non-Hodgkin's lymphoma. It combines radiotherapy with monoclonal therapy to target and kill cancer cells. Bexxar is touted by advocates, patients and some doctors for its longer remissions, much shorter treatment time and fewer side effects than chemotherapy. Although it has been highly successful for many non-Hodgkin's patients, like Mr. Reno, it has not gained wide recognition from the medical community nor patients. In the post, Reno speculates that the reasons for this could include doctor unfamiliarity with the drug, inequitable Medicare reimbursement rates, and fear of the idea of radiation therapy.

For more information and the latest news on Bexxar's discontinuation, radio-immunotherapy, and how this drug saved Reno's life, please check out The Reno Dispatch or contact Reno directly at jreno(at)san(dot)rr(dot)com.

Company/Organization Info: Jamie Reno, a patient advocate for CancerConnect.com and an award-winning correspondent for Newsweek for 20 years, has also written for The Daily Beast, The New York Times, Sports Illustrated, Rolling Stone, People, Men’s Journal, ESPN, Los Angeles Times, TV Guide, Mother Jones, MSNBC, Newsmax, Entertainment Weekly, and USA Today. Reno, who’s won more than 95 writing awards, was the lead reporter on, a Newsweek series on the 9/11 terrorist attacks that earned him and his colleagues the National Magazine Award for General Excellence, the highest award in magazine journalism. Reno is also an acclaimed author, singer-songwriter, advocate for cancer patients, and 16-year cancer survivor.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11054354.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Higher-spending hospitals have fewer deaths for emergency patients
2. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
3. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
4. Study finds doctors have exaggerated fears when starting patients on insulin
5. Diagnostic Scans Tied to Radiation Risk for Gastro Patients
6. Predictors identified for rehospitalization among post-acute stroke patients
7. Pulse pressure elevation could presage cerebrovascular disease in Alzheimers patients
8. Breast cancer patients suffer treatment-related side effects long after completing care
9. Heart failure patients with diabetes may benefit from higher glucose levels
10. Gastro Woes Often Strike Rheumatoid Arthritis Patients
11. Short Walks May Ease Fatigue in Pancreatic Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... In the early or “honeymoon” stage of a ... go out of their way to be romantic, and may exaggerate a strength or ... any online dating profile. , A recent study from Queendom.com , however, ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills needed ... top students from U.S. universities who will draw from Siemens’ deep knowledge ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... As a ... hectic schedule, a demanding job, and no time to decompress, Rabinowitz found herself drawn ... herself to meditation for its impact on her life, implementing a 20-minute-per-day meditation practice ...
(Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is killed, injured ... West Penn Burn Center, part of the Allegheny Health Network, has partnered ... you the “Space Heaters Need Space” campaign. , “Space Heaters Need Space” ...
(Date:2/12/2016)... ... 12, 2016 , ... Erlanger Agency has announced a new partnership in its ... campaign focuses on the fight against breast cancer, fundraising for a local woman named ... . , Carmen is a loving single mother of two boys who also serves ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ) is pleased to announce the promotion of ... Strategies effective Jan. 23, 2016. To learn ... ... ... ...
(Date:2/12/2016)...  SI-BONE, Inc., a medical device company that pioneered the use ... surgical (MIS) device indicated for fusion for certain disorders of the ... Medicare Administrative Contractor (MAC) covering the states of Connecticut ... , Massachusetts , Minnesota , ... , Rhode Island , Vermont ...
(Date:2/12/2016)... SEOUL, South Korea , Feb. ... Macrogen, Inc. today announced they will form a ... for precision medicine in cancer. The goal of ... digital-sorting technology with Macrogen,s high-throughput Next Generation Sequencing ... the Clinical Laboratory Improvement Amendments (CLIA) of 1988 ...
Breaking Medicine Technology: